MIRM — Mirum Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $5.61bn
- $5.92bn
- $521.31m
Mirum Q2 revenue rises 64%, raises 2025 guidance
Mirum Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Mirum Pharmaceuticals Q1 Product Sales USD 111.585 Million
Brief: Mirum’S Livmarli Now FDA Approved In Tablet Formulation
Brief: LIVMARLI Now Approved In Japan For ALGS And PFIC
Mirum Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mirum Pharmaceuticals Q4 Operating Income USD -24.222 Million
US FDA approves Mirum Pharma's genetic disorder drug (updated)
US FDA approves Mirum Pharma's genetic disorder drug
Brief: FDA Approves First Treatment For Cerebrotendinous Xanthomatosis, A Rare Lipid Storage Disease
Brief: Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule
U.S. STOCKS ON THE MOVE-Canadian National Railway, C.H. Robinson, Meta
Mirum Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Mirum rises on 2024 revenue forecast raise
Brief: Mirum Pharmaceuticals Q3 Operating Expenses USD 103.061 Million
Mirum Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Volixibat Granted Breakthrough Therapy Designation For Cholestatic Pruritus In Primary Biliary Cholangitis
Mirum Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Mirum Pharmaceuticals Q2 Basic EPS USD -0.52